SIX1 Antibody

What is SIX1 and what applications are SIX1 antibodies validated for?

SIX1 (Sine oculis homeobox homolog 1) is a transcription factor with a molecular mass of approximately 32 kDa that plays crucial roles in organ development, cell proliferation, and apoptosis . SIX1 contains a divergent DNA-binding homeodomain and an upstream SIX domain, which may participate in determining DNA-binding specificity and mediating protein-protein interactions .

SIX1 antibodies are validated for multiple applications including:

Most commercially available SIX1 antibodies have been validated in human and mouse samples, with some also showing reactivity in rat models .

What are the recommended dilutions for SIX1 antibodies in different applications?

Optimal dilutions vary depending on the specific antibody and application. Based on validation data for commonly used SIX1 antibodies:

It is strongly recommended to titrate each antibody in your specific experimental system to obtain optimal results, as signal strength can be sample-dependent .

What is the expected molecular weight of SIX1 in Western blot analysis?

The calculated molecular weight of SIX1 is 32 kDa, but the observed molecular weight typically ranges between 32-35 kDa on Western blots . This slight difference between calculated and observed weights may be due to post-translational modifications. When using rabbit monoclonal antibodies like SIX1 (D5S2S), the detected band is approximately 36 kDa .

How can I validate the specificity of SIX1 antibodies against other SIX family members?

This is a critical consideration as SIX family members share substantial sequence homology, particularly in their Six domain (SD) and homeodomain (HD) regions. To validate specificity:

• Overexpression systems: Transfect cells with expression vectors for each SIX family member (SIX1-SIX6) and perform Western blot analysis to confirm the antibody detects only SIX1. This approach was used to validate the Six1cTerm antibody, which specifically detects mouse and human SIX1 without cross-reactivity to other family members .

• Knockout controls: Use SIX1 knockout samples as negative controls. Transgenic six1 knockout mice tissues provide excellent immunohistochemical negative controls .

• Epitope selection: Choose antibodies targeting the C-terminus of SIX1, as this region has less homology with other SIX family members. The Six1cTerm antibody was raised against residues downstream of the Six1 homeodomain, representing its unique C-terminus compared to other Six family members .

Research shows that some commercial antibodies (e.g., Sigma anti-SIX1) can cross-react with human SIX2 and mouse six2 and six3, highlighting the importance of proper validation .

What criteria should be used to select a specific SIX1 antibody for my research?

Consider the following criteria when selecting a SIX1 antibody:

• Antibody type: Determine whether a polyclonal or monoclonal antibody is more suitable for your application. Polyclonal antibodies (e.g., 10709-1-AP) may provide higher sensitivity by recognizing multiple epitopes, while monoclonal antibodies (e.g., D5S2S) offer greater consistency and specificity.

• Epitope region: Choose antibodies targeting unique regions of SIX1 to minimize cross-reactivity with other SIX family members. C-terminal targeting antibodies typically offer higher specificity .

• Validated applications: Ensure the antibody has been validated for your specific application through literature or manufacturer data.

• Species reactivity: Confirm the antibody reacts with your species of interest. Common SIX1 antibodies react with human and mouse, but validation in other species may be limited .

• Published validation: Prioritize antibodies with peer-reviewed validation, especially those demonstrating specificity against other SIX family members .

What controls are essential when using SIX1 antibodies in cancer research?

When studying SIX1 in cancer contexts, include these critical controls:

• Positive controls: Use cell lines with validated SIX1 expression. A2780, HEK-293, HepG2, L02, PC-3, and SKOV-3 cells have been confirmed to express SIX1 by Western blot . For immunofluorescence, epithelial tumor cells have demonstrated positive staining .

• Negative controls: Include SIX1 knockout or knockdown samples. The use of CRISPR/Cas9 knockout systems can provide definitive negative controls .

• Expression gradients: Include samples with varying SIX1 expression levels. Cell lines with varied levels of Six1 mRNA expression correlate with protein detection by immunostaining .

• Normal tissue controls: Compare cancer samples with appropriate normal tissues, particularly considering that SIX1 expression may differ during developmental stages compared to adult tissues .

• Isotype controls: Include appropriate isotype controls to identify non-specific binding, particularly in immunohistochemistry applications.

How can I optimize SIX1 antibody performance in immunohistochemistry experiments?

To optimize SIX1 detection in IHC applications:

• Antigen retrieval: Test multiple antigen retrieval methods (heat-induced with citrate buffer vs. EDTA buffer) to maximize SIX1 epitope exposure.

• Fixation considerations: Be aware that overfixation can mask epitopes. Standard 10% neutral buffered formalin for 24-48 hours is often suitable for SIX1 detection.

• Dilution optimization: Perform titration experiments starting with the manufacturer's recommended dilution (typically 1:100 for IHC-P) . Test dilutions ranging from 1:50 to 1:200.

• Signal amplification: Consider using signal amplification systems for low-expression samples, while avoiding overamplification that may produce background.

• Nuclear staining optimization: As SIX1 is primarily a nuclear protein, ensure good nuclear membrane permeabilization and optimize counterstaining to clearly distinguish SIX1-positive nuclei.

Research has demonstrated that SIX1 immunohistochemical detection correlates with mRNA expression and can provide prognostic information in cancer samples, particularly when using validated antibodies such as Six1cTerm .

How can SIX1 antibodies be used to investigate the role of SIX1 in cancer progression and prognosis?

SIX1 antibodies offer valuable tools for investigating cancer progression:

What methodological considerations are important when using SIX1 antibodies to study protein-protein interactions?

When investigating SIX1 protein-protein interactions:

• Cross-linking optimization: If using formaldehyde or other cross-linking agents, optimize concentration and time to capture transient interactions without creating artificial associations.

• Antibody orientation: For co-immunoprecipitation, determine whether the SIX1 antibody should be used for pull-down or for detection. SIX1 antibodies validated for IP (e.g., 10709-1-AP at 0.5-4.0 μg per sample) have been successfully used in HEK-293 cells .

• Buffer composition: Optimize lysis and wash buffers to maintain interactions while minimizing background. Consider that SIX1 interacts with EYA family members for transcription activation .

• Nuclear extraction protocols: As SIX1 is primarily nuclear, ensure efficient nuclear extraction while preserving protein interactions.

• Negative controls: Include IgG controls and, when possible, SIX1-knockout samples to identify non-specific binding.

Research has shown that SIX1 mediates nuclear translocation of EYA1 and EYA2, and interacts with EYA3 and DACH1/DACH2 during myogenesis . These interactions provide positive control targets for validation.

How can SIX1 antibodies be employed in studying the tumor microenvironment and immune response?

Recent research has revealed an unexpected role for SIX1 in regulating the tumor immune microenvironment:

• Multiplex immunofluorescence: Use SIX1 antibodies in combination with immune cell markers to analyze spatial relationships between SIX1-expressing tumor cells and infiltrating immune cells.

• Flow cytometry applications: Optimize SIX1 antibodies for intracellular staining to quantify SIX1 expression levels across different cell populations.

• Single-cell analysis: Combine SIX1 antibody staining with single-cell RNA sequencing to correlate protein expression with transcriptional programs.

• Mechanistic studies: Use SIX1 antibodies to investigate how SIX1 affects TGF-β signaling and collagen deposition, as SIX1 has been shown to regulate multiple collagen genes via the TGFBR2-dependent Smad2/3 activation pathway .

How can SIX1 antibodies be used in studying cell differentiation and developmental processes?

SIX1 plays critical roles in development, offering important research applications:

• Lineage tracing: Use SIX1 antibodies to track mesoderm- and neural crest-derived lineages during embryonic development .

• Muscle differentiation: Apply SIX1 antibodies to study myogenic transcription factor dynamics, as SIX1 has been shown to maintain the undifferentiated state in rhabdomyosarcoma by controlling enhancer activity and MYOD1 occupancy .

• Brown adipocyte differentiation: Investigate SIX1's role in promoting brown adipocyte differentiation using validated antibodies .

• Developmental timing studies: Track SIX1 expression across different developmental stages to understand temporal regulation of organogenesis.

• CRISPR-mediated studies: Combine SIX1 antibodies with CRISPR-based gene editing to analyze the impact of SIX1 mutations or knockout on developmental processes .

What are the technical challenges in using SIX1 antibodies for chromatin immunoprecipitation (ChIP) experiments?

ChIP experiments with SIX1 antibodies present several technical challenges:

• Epitope accessibility: SIX1 binds DNA through its homeodomain, which may be partially masked during chromatin binding, potentially affecting antibody recognition. Choose antibodies targeting regions outside the DNA-binding domain.

• Cross-linking optimization: DNA-binding proteins often require careful optimization of cross-linking conditions to capture transient interactions without creating excessive background.

• Binding site specificity: SIX1 binds the 5'-TCA[AG][AG]TTNC-3' motif present in the MEF3 element in various promoters and enhancers . Design controls that include these known binding sites.

• Co-factor interactions: SIX1 interacts with EYA family members for transcriptional activation , which may affect epitope accessibility in ChIP experiments.

• Low abundance challenges: In some cell types, SIX1 may be expressed at low levels, requiring optimization of cell numbers and precipitation conditions.

For successful ChIP experiments, consider monitoring SIX1 binding to known targets such as MYC, CCND1, EZR, IGFBP5, CCNA1, or the MEF3 element in the MYOG promoter and CIDEA enhancer .

How does SIX1 protein expression correlate with mRNA levels across different experimental systems?

Understanding the relationship between SIX1 protein and mRNA expression is crucial for experimental design:

• Post-transcriptional regulation: In Ewing's sarcoma cell lines, all examined ES cell lines displayed increased levels of SIX1 protein despite only the A673 cell line showing increased SIX1 mRNA compared to human mesenchymal stem cells, suggesting that SIX1 is primarily controlled post-transcriptionally in this cancer type .

• Linear correlation in some systems: In ovarian cancer cell lines, a correlation between SIX1 mRNA levels and protein detection by immunostaining has been observed, with median cell line SIX1 expression at 0.39 RSR and a range of 0-10.0 RSR .

• Tumorigenicity threshold: In ovarian cancer models, all cell lines with SIX1 ≥0.37 RSR were tumorigenic while all cell lines with SIX1 expression below 0.37 RSR were not tumorigenic, demonstrating a potential threshold effect .

• Validation methodology: When establishing new models, it's advisable to validate SIX1 expression at both mRNA (qRT-PCR) and protein (Western blot, immunostaining) levels to understand the relationship in your specific system.

How can researchers integrate SIX1 antibody-based detection with other -omics approaches?

Modern research benefits from integrating antibody-based detection with other technologies:

• Proteogenomic integration: Combine SIX1 antibody-based proteomics with genomic analysis to identify mutations or variations that affect protein expression or function. This is particularly relevant as SIX1 mutations have been identified in branchio-oto-renal syndrome.

• ChIP-seq analysis: Use SIX1 antibodies for ChIP-seq to map genome-wide binding sites, then integrate with RNA-seq data to identify direct transcriptional targets. This approach has revealed SIX1's regulation of numerous genes including MYC, CCND1, and EZR .

• Single-cell multi-omics: Combine SIX1 antibody-based protein detection with single-cell transcriptomics to understand heterogeneity in SIX1 expression and function across cell populations.

• Spatial transcriptomics integration: Correlate SIX1 immunohistochemistry with spatial transcriptomics data to understand the spatial context of SIX1 function in tissues and tumors.

• Phospho-proteomics connection: Integrate SIX1 detection with phospho-proteomics to understand how post-translational modifications affect SIX1 function and protein-protein interactions.